Management challenge with drotrecogin alfa (activated)

American Journal of Health-System Pharmacy

Volumn 59, Issue SUPPL. 1, 2002, Pages

  Vanscoy, Gordon J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Clinical studies; Drotrecogin alfa; Economics; Proteins; Sepsis

Indexed keywords

DROTRECOGIN;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INTENSIVE CARE UNIT; PHARMACY; PRIORITY JOURNAL; SEPSIS;

EID: 0036160814     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.suppl_1.s23     Document Type: Conference Paper

References (16)

1. Drug-related morbidity and mortality: A cost-of-illness model
2. Drug-related morbidity and mortality: Updating the cost-of-illness model
3. Teamwork used to be a money saver; now it's a lifesaver
4. Incidence, cost, and outcomes of severe sepsis in the United States
5. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients
6. Efficacy and safety of recombinant human activated protein C for severe sepsis
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
8. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
9. Effect of recombinant human protein C (rhAPC) on organ dysfunction and functional recovery in severe sepsis
10. Some guidelines on the use of cost effectiveness leauge tables
11. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
12. Company update: Eli Lilly and Company. Zovant (for sepsis) - A potential blockbuster